Development of Immunotherapeutic Products for the Treatment of Methamphetamine Addiction (U01)

The summary for the Development of Immunotherapeutic Products for the Treatment of Methamphetamine Addiction (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Development of Immunotherapeutic Products for the Treatment of Methamphetamine Addiction (U01): The objective of this solicitation is to support research in the design, synthesis, and pre-clinical evaluation of vaccines developed from methamphetamine-protein conjugates (heretofore referred to as methamphetamine conjugate vaccines or MCVs) for the active immunotherapeutic treatment of methamphetamine addiction. This initiative is intended to support activities focused on the development of promising MCVs as clinical candidates and to provide sufficient data required for the submission of an Investigational New Drug (IND) application to the Food and Drug Administration in support of early clinical evaluation of the new MCVs. Basic research/mechanistic studies or clinical trials will not be supported. NIDA has set aside $2.5M in total costs in FY2007 for applications submitted in response to this research announcement. It is anticipated that approximately 2 to 3 applications will be awarded. This RFA uses the NIH U01 mechanism and is open to Public/State Controlled Institution of Higher Education, Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education, Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education), Small Business, For-Profit Organization (Other than Small Business), State Government, U.S. Territory or Possession, Indian/Native American Tribal Government (Federally Recognized), Indian/Native American Tribal Government (Other than Federally Recognized), Indian/Native American Tribally Designated Organization, Hispanic-serving Institution, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Regional Organization, Other(s): Eligible agencies of the Federal government; Faith-based or community based organizations.
Federal Grant Title: Development of Immunotherapeutic Products for the Treatment of Methamphetamine Addiction (U01)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-07-004
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: No deadline provided
Original Application Deadline: Jan 12, 2007
Posted Date: Oct 18, 2006
Creation Date: Oct 18, 2006
Archive Date: Feb 11, 2007
Total Program Funding: $2,500,000
Maximum Federal Grant Award: $1,000,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Native American tribal governments (Federally recognized) For profit organizations other than small businesses County governments City or township governments Independent school districts Private institutions of higher education Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility
Foreign institutions are not eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply. Foreign institutions are not eligible to apply as the primary institution, but may enter into a consortium or subcontract with a domestic institution as the primary applicant.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, An...
Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
Research Networks for the Study of Recovery Support Services for Persons Treated with Medi...
The Rat Opioid Genome Project: Clinical Trials not Allowed (U01- Clinical Trial Not Allowe...
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2020